Massachusetts General Hospital Psychopharmacology and Neurotherapeutics

2. Auflage 2024
ISBN: 978-0-443-11972-9
Verlag: Elsevier Health Sciences

Buch, Englisch, 256 Seiten, Format (B × H): 214 mm x 272 mm, Gewicht: 712 g

Offering user-friendly, authoritative guidance on cutting-edge psychopharmacologic and somatic treatments for psychiatric and neurologic conditions, Massachusetts General Hospital Psychopharmacology and Neurotherapeutics, 2nd Edition, helps you put today's best approaches to work for your patients. Composed of topical chapters primarily from the third edition of Stern et al.’s Massachusetts General Hospital Comprehensive Clinical Psychiatry, this fully revised resource focuses on current psychotropic treatments, electroconvulsive therapy, and neurotherapeutics, making it an ideal quick reference for psychiatrists, psychologists, internists, and nurse practitioners. - Brings you up-to-date information on key topics in the field, including the application of anticonvulsants, anxiolytics, mood stabilizers, and psychostimulants; drug-drug interactions; side effects; treatment adherence; and more.
- Includes detailed coverage of antidepressants, antipsychotics, and antianxiety medications, as well as advances in caring for patients with treatment-resistant depression and new legal considerations when prescribing psychotropics.
- Covers recent progress on the use of neurotherapeutic interventions, such as transcranial magnetic stimulation, vagal nerve stimulation, and deep brain stimulation.
- Contains a new chapter on the pharmacotherapy of movement disorders (derived from Stern et al.’s MGH Handbook of General Hospital Psychiatry, 8th Edition).
- Features a user-friendly, highly templated format with abundant boxed summaries, bulleted points, case histories, algorithms, updated references, and suggested readings.
- Offers updated DSM-5-TR criteria alongside peerless, hands-on advice from members of the esteemed MGH Department of Psychiatry.
- An eBook version is included with purchase. The eBook allows you to access all of the text, figures, and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date.

Autoren/Hrsg.

Stern, Theodore A

Camprodon, Joan A.

Fava, Maurizio

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Neuropharmakologie, Psychopharmakologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Psychiatrie, Sozialpsychiatrie, Suchttherapie

Inhaltsverzeichnis

1 Psychiatric Neuroscience: Incorporating Pathophysiology into Clinical Case Formulation
2 Treatment Adherence
3 Pharmacological Approaches to Depression and Treatment-Resistant Depression
4 Lithium and Its Role in Psychiatry
5 The Use of Antiepileptic Drugs in Psychiatry
6 The Pharmacotherapy of Anxiety Disorders
7 Pharmacotherapy of Attention-Deficit Hyperactivity Disorder Across the Life Span
8 Natural Medications in Psychiatry
9 Antipsychotic Drugs
10 Patients with Abnormal Movements
11 Pathophysiology, Psychiatric Co-morbidity, and Treatment of Pain
12 Psychiatric Illness During Pregnancy and the Post-partum Period
13 Side Effects of Psychotropic Medications
14 Drug-Drug Interactions in Psychopharmacology
15 Pharmacotherapy of Neurocognitive Disorders and Dementia
16 Pharmacotherapy of Substance Use Disorders
17 Pharmacotherapy of Sexual Disorders and Sexual Dysfunction
18 Device Neuromodulation and Brain Therapies
19 Legal Considerations for Mental Health Providers

Über Autor(innen)

Fava, Maurizio
Dr. Maurizio Fava is Chair of the Department of Psychiatry at the Massachusetts General Hospital (MGH). Dr. Fava obtained his MD from University of Padova School of Medicine (residency in endocrinology); he completed residency training in psychiatry at the MGH. He founded and was director of the hospital's Depression Clinical and Research Program (DCRP) from 1990 to 2014. In 2007, he founded and is now Executive Director of the MGH Clinical Trials Network and Institute (CTNI), the first academic CRO specialized in planning and coordination of multi-center clinical trials in psychiatry. Under Dr. Fava's direction, the DCRP became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. His prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly acting antidepressant therapies. Dr. Fava is a world leader in the field of depression. He has authored or co-authored more than 900 original articles published in medical journals with international circulation, edited eight books, and has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $150 million.

Camprodon, Joan A.
Dr. Joan A. Camprodon is board-certified in Psychiatry, and Behavioral Neurology & Neuropsychiatry. His research (as Director of the Laboratory for Neuropsychiatry and Neuromodulation) uses multimodal combinations of neuroimaging and brain stimulation to investigate neural circuitry and plasticity in a translational manner. His lab works with a wide range of noninvasive and invasive neuromodulation techniques including transcranial electrical current stimulation (tECS), transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT) and deep brain stimulation (DBS) among others. The scope of his research includes basic, translational and clinical projects focused on circuit neuroscience.